Boris A. Mueller, MD, MPH
Director, Radiation Oncology, MSK Bergen
Breast Cancer; Lung Cancer; Bladder Cancer; Prostate Cancer; Gynecologic Tumors, Sarcoma; CNS Tumors, Spine Tumors, Head & Neck Cancer
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Mueller accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Johns Hopkins School of Medicine (1998) MPH, Johns Hopkins School of Public Health
Radiation Oncology - Memorial Sloan Kettering Cancer Center
I am a radiation oncologist who cares for patients at Memorial Sloan Kettering Bergen. Our team approach allows my colleagues and me to deliver state-of-the-art care close to home. I see about 400 patients each year, and have been working at Memorial Sloan Kettering since I finished my residency training there in 2003.
I love working with patients in an institution where patient care, medical research, and cutting-edge technology intersect. I have a degree in electrical engineering and worked as an engineer before attending medical school at Johns Hopkins University. I was attracted to a field that was heavily dependent on technology but also involved a great deal of patient contact. Radiation oncology proved to be a great fit.
It’s an inspiring time in our field. Thanks to new advances, we can now use stereotactic radiation therapy to deliver highly precise doses of radiation that destroy tumors and spare healthy tissue. I have been involved in research on improving the quality of cancer care through telemedicine, which allows doctors to diagnose and treat disease remotely.
My research has more recently focused on implementing tattooless radiotherapy at MSKCC for breast cancer, prostate cancer, and spine tumors. With the use of a new optical monitoring system (AlignRT) on our radiation machines, we will soon be able to treat patients without relying on tattoos. An additional research interest of mine is learning how to reduce the risk of radiation-associated secondary cancers.
All patients are nervous during their first appointment — that’s normal. I work very hard with our nursing staff to make a strong personal connection with everyone I meet. Once a patient is under my care, I will always be there for them, even many years later.
I work very hard with our nursing staff to make a strong personal connection with everyone I meet. Once a patient is under my care, I will always be there for them, even many years later.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Braunstein LZ, Gillespie EF, Hong L, Xu A, Bakhoum SF, Cuaron J, Mueller B, McCormick B, Cahlon O, Powell S, Khan AJ. Breast Radiation Therapy Under COVID-19 Pandemic Resource Contstraints-Approaches to Defer or Shorten From a Comprehensive Cancer Center in the US. Adv Radiat Oncol 2020.
Bitencourt A, Rossi Saccarelli C, Morris EA, Flynn J, Zhigang Z, Khan AK, Gillesphie E, Caholon O, Mueller B, Cuaron J, McCormick B, Powell S, Plitas G, Razavi P, Pinker K, Riedl C, Sutton E, Braunstein L. Regional Lymph Node Involvement Among Patients with De Novo Metastatic Breast Cancer. JAMA Netw Open 2020.
Fitzgerald K, Flynn J, Zhang Z, Cost Z, Mueller B, Gillespie EF, McCormick B, Khan A, Cahlon O, Powell S, Braunstein L. Patterns of Recurrence Among Higher-Risk Patient Receiving Daily External Beam APBI to 40Gy in 10 Fractions. Adv Radiat Oncol 2019.
Sillanpann J, Lovelock M, Mueller B. The effects of the orthopedic metal artifact reduction (O-MAR) algorithm on contouring and dosimetry of head and neck radiotherapy patients. Med Dosim 2019.
Ho AY, Ballangrud A, Li G, Gupta GP, McCormick B, Gewanter R, Gelblum D, Zinovoy M, Mueller B, Mychalczak B. Long-Term Pulmonary Outcomes of a Feasibility Study of Inverse-Planned, Multibeam IMRT in Node-Positive Breast Cancer Patients Receiving Regional Nodal Irradiation. IJROBP 2018
Fury MG, Sherman EJ, Rao SS, Wolden S, Smith-Marrone S, Mueller B, Ng KK, Dutta PR, Gelblum DY, Lee JL, Shen R, Kurz S, Katabi N, Haque S, Lee NY. Phase I Study of Weekly nab-Paclitaxel + Weekly Cetuximab + IMRT in patients with stage III-IVB Head and Neck Squamous Cell Carcinoma. Ann Oncol 2014; 3:689-94.
Song Y, Obcemea C, Mueller B, Mychalczak B. Image-Guided Volumetric Modulated Arc Therapy (IG-VMAT) for Prostate Cancer. IFMBE (International Federation for Medical and Biomedical Engineering) Proceedings 2012; Volume 37, 223-226.
Song Y, Mueller B, Obcemea C, Mychalczak B. Feasibility of Implementing Stereotactic Body Radiation Therapy Using a Non-commercial Volumetric Modulated Arc Therapy Treatment Planning System for Early Stage Lung Cancer. IEEE (Institute for Electronic and Electrical Engineers) Engineering in Medicine and Biology 2011; 409-412.
Mueller BA, Obcemea C, Lee J, Sim S. Pilot Study of a Radiation Oncology Telemedicine Platform. Journal of Radiation Oncology Informatics 2010; 2:1:20-30.
Song Y, Zhang P, Obcemea C, Mueller B, Burman C, Mychalczak B. Dosimetric Effects of Gantry Angular Acceleration and Deceleration in Volumetric Modulated Radiation Therapy. IFMBE (Proceedings, World Congress on Medical Physics and Biomedical Engineering 2009; 25/1: 1046-1050.
Song Y, Zhang P, Wang P, Obcemea C, Mueller B, Burman C, Mychalczak B. The Development of a Novel Radiation Treatment Modality – Volumetric Modulated Arc Therapy. IEEE-Engineering in Medicine and Biology 2009; 3401 – 3404.
Song Y, Mueller B, Chan M, Sim S, Mychalczak B, Huang X. A Hybrid Method for Reliable Registration of Digitally Reconstructed Radiographs and kV X-ray Images for Image-Guided Radiation Therapy for Prostate Cancer. SPIE (Society of Photo-Optical Instrumentation Engineers) Medical Imaging 2008; Vol. 6918.
Song Y, Huang X, Mueller B, Mychalczak B. Phase Impact Factor: A Novel Parameter for Determining Optimal CT Phase in 4D Radiation Therapy Treatment Planning for Mobile Lung Cancer. SPIE Medical Imaging 2008: Vol. 6918.
Li G, Citrin D, Camphausen K, Mueller B, Mychalczak B, Miller RW, Song Y. Advances in 4D Medical Imaging and 4D radiation therapy. Technology in Cancer Research and Treatment 2008; Vol.1, 67-81.
Song Y, Mueller B, Burman C, Mychalczak B. From intensity modulated radiation therapy to 4D radiation therapy – An advance in targeting mobile lung tumors. Conf Proc IEEE Med Biol Soc. 2007; 226-9.
Song Y, Mueller B, Burman C, Mychalczak B, Song Y. A model-aided segmentation in urethra identification based on an atlas human autopsy image for intensity modulated radiation therapy. Conf Proc IEEE Eng Med Biol Soc. 2007; 1:3532-5.
Yamada Y, Bhatia S, Zaider M, Cohen G, Donat M, Eastham J, Rabbani F, Schupak K, Lee J, Mueller B, Zelefsky MJ. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 2006; 5(3):157-64.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Boris A. Mueller discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.